Xenleta™

	Next higher product group	lefamulin (BC-3781)
	Status	2019-08-19 registration start
	Organisation	Nabriva Therapeutics Forschungs GmbH
	Today	Nabriva Therapeutics GmbH
	Group	Nabriva (Group)

Record changed: 2023-07-10

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for lefamulin (BC-3781)

[1] F2G Ltd.. (4/12/21). "Press Release: Francesco Maria Lavino Appointed Chief Executive Officer of F2G Ltd". Manchester & Vienna....
[2] Nabriva Therapeutics plc. (2/26/21). "Press Release: Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer". Dublin & King of Prussia, PA....
[3] Nabriva Therapeutics plc. (8/19/19). "Press Release: Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP)". Dublin....
[4] Nabriva Therapeutics plc. (2/19/19). "Press Release: Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults". Dublin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]